News from sponsors

Opdivo is reimbursed as of 1st of January in Lung (NSCLC), RCC (renal) and Hodgkin in monotherapy, as well as in melanoma in combination with Yervoy.

More information can be read in the article of BMS (PDF)

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf

 

The cancer immunity cycle: a framework for cancer immunotherapy

More information can be read in the article of Roche (PDF)